PROVIDENCE – November 05, 2026 -- Electronic Genome Mapping (EGM) detected every abnormality identified by standard cytogenetic testing in an initial study, according to researchers from Augusta University and The University of Texas MD Anderson Cancer Center. They will present the findings at the Association for Molecular Pathology (AMP) 2026 Annual Meeting, November 10-14 in Seattle, Nabsys 2.0, LLC said.
Augusta and MD Anderson pathologists present EGM data on November 13
Ravindra Kolhe, M.D., Ph.D., Professor and Chair of Pathology at Augusta University, and Rashmi Kanagal-Shamanna, M.D., Professor of Hematopathology and Molecular Diagnostics at MD Anderson, will present at the Innovation Spotlight Session (stage 1). The slot runs 9:30-10:00 a.m. PT on Friday, November 13. The talk is titled "Electronic Genome Mapping for Structural Variant Detection: Implications for Advancing Clinical Research in Heme Malignancies."
EGM consolidates a multi-assay workflow into one test on the OhmX Platform
Characterizing hematologic malignancies often requires karyotyping, FISH, chromosomal microarray and sequencing. EGM analyzes structural and copy number variants genome-wide in a single assay on the Nabsys OhmX Platform.
Kolhe said the initial study also yielded additional molecular insights in complex cases. He plans to discuss how EGM could streamline cytogenomic analysis in clinical research.
Kanagal-Shamanna said conventional cytogenetics depends on dividing bone marrow aspirates collected through invasive procedures. These samples can be hemodilute and sometimes too small for assays. Her preliminary data indicate EGM can detect translocations, deletions and complex rearrangements directly from peripheral blood. It needs no culture and offers resolution far beyond karyotyping.
Nabsys demonstrates cloud analysis software at Booth #937
Nabsys will demonstrate Nabsys Navigator, its cloud-based platform for EGM analysis and visualization. Available pipelines include SV-Discover for genome-wide structural variant analysis and SV-Verify for confirming structural variants identified by other technologies.
Attendees can preview forthcoming hematologic malignancy analysis software. They can also give feedback on data presentation, navigation, access to information and interface design.
Founder and CEO Barrett Bready, M.D., said "collaboration with the hematopathology community is essential" to EGM's success. He said the researchers' work is critical to building the evidence and clinical research understanding needed for broader adoption.
The OhmX Platform is for Research Use Only and not for use in diagnostic procedures.